Associations - CDK4 (Cyclin-dependent kinase 4)

CDK4 amplification	Non Small Cell Lung Cancer	CDK4 amplification	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
CDK4 amplification	Liposarcoma	CDK4 amplification	Liposarcoma	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2
CDK4 overexpression	Osteosarcoma	CDK4 overexpression	Osteosarcoma	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2
CDK4 overexpression	Soft Tissue Sarcoma	CDK4 overexpression	Soft Tissue Sarcoma	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2
CDK4 amplification	Mucosal Melanoma	CDK4 amplification	Mucosal Melanoma	dalpiciclib Sensitive: C2 – Inclusion Criteria dalpiciclib Sensitive : C2	dalpiciclib Sensitive: C2 – Inclusion Criteria dalpiciclib Sensitive : C2
CDK4 mutation + EGFR mutation	Non Small Cell Lung Cancer	CDK4 mutation + EGFR mutation	Non Small Cell Lung Cancer	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
CDK4 amplification	Soft Tissue Sarcoma	CDK4 amplification	Soft Tissue Sarcoma	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
CDK4 mutation + HR positive	HER2 Negative Breast Cancer	CDK4 mutation + HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
CDK4 amplification	Melanoma	CDK4 amplification	Melanoma	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3
CDK4 overexpression	Gastrointestinal Stromal Tumor	CDK4 overexpression	Gastrointestinal Stromal Tumor	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3	imatinib Sensitive: C3 – Early Trials imatinib Sensitive : C3
CDK4 amplification	Osteosarcoma	CDK4 amplification	Osteosarcoma	palbociclib + lenvatinib Sensitive: C3 – Early Trials palbociclib + lenvatinib Sensitive : C3	palbociclib + lenvatinib Sensitive: C3 – Early Trials palbociclib + lenvatinib Sensitive : C3
CDK4 amplification	Diffuse Large B Cell Lymphoma	CDK4 amplification	Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials R-CHOP Resistant : C3	R-CHOP Resistant: C3 – Early Trials R-CHOP Resistant : C3

CDK4 (Cyclin-dependent kinase 4)

Associations(20)

Associations
(20)